Lysosome-mediated chemoresistance in acute myeloid leukemia

Abstract

Despite the outstanding advances in understanding the biology underlying the pathophysiology of acute myeloid leukemia (AML) and the promising preclinical data published lastly, AML treatment still relies on a classic chemotherapy regimen largely unchanged for the past five decades. Recently, new drugs have been approved for AML, but the real clinical benefit is still under evaluation. Nevertheless, primary refractory and relapse AML continue to represent the main clinical challenge, as the majority of AML patients will succumb to the disease despite achieving a complete remission during the induction phase. As such, treatments for chemoresistant AML represent an unmet need in this disease. Although great efforts have been made to decipher the biological basis for leukemogenesis, the mechanism by which AML cells become resistant to chemotherapy is largely unknown. The identification of the signaling pathways involved in resistance may lead to new combinatory therapies or new therapeutic approaches suitable for this subset of patients. Several mechanisms of chemoresistance have been identified, including drug transporters, key secondary messengers, and metabolic regulators. However, no therapeutic approach targeting chemoresistance has succeeded in clinical trials, especially due to broad secondary effects in healthy cells. Recent research has highlighted the importance of lysosomes in this phenomenon. Lysosomes’ key role in resistance to chemotherapy includes the potential to sequester drugs, central metabolic signaling role, and gene expression regulation. These results provide further evidence to support the development of new therapeutic approaches that target lysosomes in AML.

Keywords

Lysosome / chemoresistance / AML / lysosomotropic drug / lysosomal sequestration / refractory AML

References

[1] Döhner H,Bloomfield CD.Acute myeloid leukemia.N Engl J Med2015;373:1136-52

[2] Yates JW,Ellison RR.Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.Cancer Chemother Rep1973;57:485-8

[3] Estey E,Emadi A,Gale RP.Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?.Leukemia2020;34:671-81

[4] Tran AA,Prasad V.Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia.Leuk Res2020;96:106420

[5] Gurnari C,Visconte V.The interactome between metabolism and gene mutations in myeloid malignancies.Int J Mol Sci2021;22:3135 PMCID:PMC8003366

[6] Long L,Lei ZN.Genetic biomarkers of drug resistance: a compass of prognosis and targeted therapy in acute myeloid leukemia.Drug Resist Updat2020;52:100703

[7] Alexa-Stratulat T,Gašparović AČ,Riganti C.What sustains the multidrug resistance phenotype beyond ABC efflux transporters?.Drug Resist Updat2019;46:100643

[8] Fajardo-Orduña GR,Aguiñiga-Sánchez I,Weiss-Steider B.Inhibitors of chemoresistance pathways in combination with Ara-C to overcome multidrug resistance in AML. A mini review.Int J Mol Sci2021;22:4955 PMCID:PMC8124548

[9] Farge T,de Toni F.Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism.Cancer Discov2017;7:716-35

[10] Tian Y,Wang Z.Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.PLoS One2014;9:e84150 PMCID:PMC3885535

[11] Bosc C,Bousard A.Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.Nat Cancer2021;2:1204-23

[12] Roca-Portoles A,Sumpton D.Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition.Cell Death Dis2020;11:616 PMCID:PMC7426836

[13] Niu X,Chen M.Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia.Blood2021;137:3641-55 PMCID:PMC8462401

[14] Appelqvist H,Kågedal K.The lysosome: from waste bag to potential therapeutic target.J Mol Cell Biol2013;5:214-26

[15] Peng W,Krainc D.Mitochondria-lysosome contacts regulate mitochondrial Ca²⁺ dynamics via lysosomal TRPML1.Proc Natl Acad Sci U S A2020;117:19266-75 PMCID:PMC7430993

[16] Wong YC,Peng W.Regulation and function of mitochondria-lysosome membrane contact sites in cellular homeostasis.Trends Cell Biol2019;29:500-13 PMCID:PMC8475646

[17] Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue.Biochem J1955;60:604-17 PMCID:PMC1216159

[18] Takeshige K,Tsuboi S,Ohsumi Y.Autophagy in yeast demonstrated with proteinase-deficient mutants and conditions for its induction.J Cell Biol1992;119:301-11 PMCID:PMC2289660

[19] Duve C, Wattiaux R. Functions of lysosomes.Annu Rev Physiol1966;28:435-92

[20] Lamming DW.Lysosome: the metabolic signaling hub.Traffic2019;20:27-38 PMCID:PMC6294686

[21] Forgac M.Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology.Nat Rev Mol Cell Biol2007;8:917-29

[22] Zhang Z,Lu T,Wei Y.Role of lysosomes in physiological activities, diseases, and therapy.J Hematol Oncol2021;14:79 PMCID:PMC8120021

[23] Trivedi PC,Pulinilkunnil T.Lysosomal biology and function: modern view of cellular debris bin.Cells2020;9:1131 PMCID:PMC7290337

[24] Tang T,Wang D.The role of lysosomes in cancer development and progression.Cell Biosci2020;10:131 PMCID:PMC7677787

[25] Sukhai MA,Hurren R.Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.J Clin Invest2013;123:315-28 PMCID:PMC3533286

[26] Samudio I,Fiegl M.Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.J Clin Invest2010;120:142-56 PMCID:PMC2799198

[27] Eppert K,Lechman ER.Stem cell gene expression programs influence clinical outcome in human leukemia.Nat Med2011;17:1086-93

[28] Kikushige Y,Takayanagi S.TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.Cell Stem Cell2010;7:708-17

[29] Gentles AJ,Page P,Alizadeh AA.Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.JAMA2010;304:2706-15 PMCID:PMC4089862

[30] Metzeler KH,Bloomfield CD.An 86-probe gene expression signature can predict survival in AML with normal karyotype independently of FLT3 ITD and NPM1 mutation status - a collaborative study from the AMLCG and CALGB study groups.Blood2007;110:596-596

[31] Rapin N,Jendholm J.Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients.Blood2014;123:894-904

[32] Metzeler KH,Bloomfield CD.Cancer and Leukemia Group B, German AML Cooperative GroupAn 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.Blood2008;112:4193-201 PMCID:PMC2954679

[33] Ng SW,Kennedy JA.A 17-gene stemness score for rapid determination of risk in acute leukaemia.Nature2016;540:433-7

[34] Herold T,Batcha AMN.A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.Haematologica2018;103:456-65 PMCID:PMC5830382

[35] Valk PJ,Beijen MA.Prognostically useful gene-expression profiles in acute myeloid leukemia.N Engl J Med2004;350:1617-28

[36] Steinbach D,Sauerbrey A.ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia.Clin Cancer Res2006;12:4357-63

[37] Li Z,He C.Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.J Clin Oncol2013;31:1172-81 PMCID:PMC3595425

[38] Chapuy B,Radunski U.Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration.Leukemia2008;22:1576-86

[39] Aasebø E,Hernandez-Valladares M.Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia.Expert Rev Hematol2018;11:13-24

[40] Majeti R,Tian Q.Dysregulated gene expression networks in human acute myelogenous leukemia stem cells.Proc Natl Acad Sci2009;106:3396-401 PMCID:PMC2642659

[41] Benoit YD,Risueño RM.Sam68 allows selective targeting of human cancer stem cells.Cell Chem Biol2017;24:833-844.e9

[42] Wang Y,Sinha AU.The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.Science2010;327:1650-3 PMCID:PMC3084586

[43] Cruciat CM,Acebron SP.Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling.Science2010;327:459-63

[44] Tuttle AM,Schilling TF.Rabconnectin-3a regulates vesicle endocytosis and canonical Wnt signaling in zebrafish neural crest migration.PLoS Biol2014;12:e1001852 PMCID:PMC4011682

[45] Wang Y,Malek SN,Liu Y.Targeting HIF1α eliminates cancer stem cells in hematological malignancies.Cell Stem Cell2011;8:399-411 PMCID:PMC3084595

[46] Kannan S,Hall MG.Notch activation inhibits AML growth and survival: a potential therapeutic approach.J Exp Med2013;210:321-37 PMCID:PMC3570106

[47] Lobry C,Ndiaye-Lobry D.Notch pathway activation targets AML-initiating cell homeostasis and differentiation.J Exp Med2013;210:301-19 PMCID:PMC3570103

[48] Kobia F,Deflorian G.Pharmacologic inhibition of vacuolar H+ ATPase reduces physiologic and oncogenic Notch signaling.Mol Oncol2014;8:207-20 PMCID:PMC5528540

[49] Vaccari T,Cortese K,Bilder D.The vacuolar ATPase is required for physiological as well as pathological activation of the Notch receptor.Development2010;137:1825-32 PMCID:PMC2867318

[50] Yan Y,Schüpbach T.The vacuolar proton pump, V-ATPase, is required for notch signaling and endosomal trafficking in Drosophila.Dev Cell2009;17:387-402 PMCID:PMC2758249

[51] Xu Q,Scialla TJ,Carroll M.Survival of acute myeloid leukemia cells requires PI3 kinase activation.Blood2003;102:972-80

[52] Récher C,Demur C.Antileukemic activity of rapamycin in acute myeloid leukemia.Blood2005;105:2527-34

[53] Yilmaz OH,Theisen BK.Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.Nature2006;441:475-82

[54] Tamburini J,Bardet V.Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.Blood2007;110:1025-8

[55] Récher C,Demur C.mTOR, a new therapeutic target in acute myeloid leukemia.Cell Cycle2005;4:1540-9

[56] Marino ML,Djavaheri-Mergny M.Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells.Cell Death Dis2010;1:e87 PMCID:PMC3035900

[57] Carneiro BA,Altman JK,Platanias LC.Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.Cancer Biol Ther2015;16:648-56 PMCID:PMC4622839

[58] Chapuis N,Green AS.Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.Clin Cancer Res2010;16:5424-35

[59] Halaby R.Influence of lysosomal sequestration on multidrug resistance in cancer cells.Cancer Drug Resist2019;2:31-42

[60] Ferrao P,Cole S.Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia.Leukemia Research2001;25:395-405

[61] Yamagishi T,Sharp DM,Jansson PJ.P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.J Biol Chem2013;288:31761-71 PMCID:PMC3814770

[62] Fu D.Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.Am J Physiol Cell Physiol2007;292:C1543-52

[63] Shapiro AB,Lee P,Ling V.Functional intracellular P-glycoprotein.Int J Cancer1998;76:857-64

[64] MacIntyre AC.The potential role of lysosomes in tissue distribution of weak bases.Biopharm Drug Dispos1988;9:513-26

[65] Duve C, De Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Lysosomotropic agents.Biochem Pharmacol1974;23:2495-531

[66] Gotink KJ,Labots M.Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.Clin Cancer Res2011;17:7337-46 PMCID:PMC4461037

[67] Van Der Steen N,Dekker H.Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.J Cell Physiol2020;235:8085-97 PMCID:PMC7540474

[68] Klerk DJ, Honeywell RJ, Jansen G, Peters GJ. Transporter and lysosomal mediated (multi)drug resistance to tyrosine kinase inhibitors and potential strategies to overcome resistance.Cancers (Basel)2018;10:503 PMCID:PMC6315453

[69] Hurwitz SJ,Mizunuma N.Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.Blood1997;89:3745-54

[70] Herlevsen M,Owens CR,Theodorescu D.Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes.Mol Cancer Ther2007;6:1804-13

[71] Smith PJ,Fox ME.Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage.Cancer Res1992;52:4000-8

[72] Marshall LA,Hofmann L,Schneider E.Increased lysosomal uptake of methotrexate-polyglutamates in two methotrexate-resistant cell lines with distinct mechanisms of resistance.Biochem Pharmacol2005;71:203-13

[73] Groth-Pedersen L,Høyer-Hansen M,Jäättelä M.Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine.Cancer Res2007;67:2217-25

[74] Samimi G,Holzer AK,Howell SB.Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.Mol Pharmacol2004;66:25-32

[75] Shimomura M,Itoh K.Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.Int J Oncol2012;40:995-1004 PMCID:PMC3584812

[76] Zhang J,Wong YK.Docetaxel enhances lysosomal function through TFEB activation.Cell Death Dis2018;9:614 PMCID:PMC5966422

[77] Duvvuri M.A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict.Mol Pharm2005;2:440-8

[78] Zhitomirsky B.Lysosomes as mediators of drug resistance in cancer.Drug Resist Updat2016;24:23-33

[79] Zhao B,Gu JN.TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer.Cell Death Discov2020;6:12 PMCID:PMC7066197

[80] Medina DL,Peluso I.Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB.Nat Cell Biol2015;17:288-99 PMCID:PMC4801004

[81] Li DL,Ding G.Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification.Circulation2016;133:1668-87 PMCID:PMC4856587

[82] Groth-Pedersen L.Combating apoptosis and multidrug resistant cancers by targeting lysosomes.Cancer Lett2013;332:265-74

[83] Sundler R.Lysosomal and cytosolic pH as regulators of exocytosis in mouse macrophages.Acta Physiol Scand1997;161:553-6

[84] Kazmi F,Pope C.Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).Drug Metab Dispos2013;41:897-905 PMCID:PMC3608459

[85] Medina DL,Bouche V.Transcriptional activation of lysosomal exocytosis promotes cellular clearance.Dev Cell2011;21:421-30 PMCID:PMC3173716

[86] Zhitomirsky B.The role of cytoplasmic-to-lysosomal pH gradient in hydrophobic weak base drug sequestration in lysosomes.Can Cell Microenviron2015;

[87] Gervasoni JE,Krishna S.Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.Cancer Res1991;51:4955-63

[88] Breuninger LM,Gaughan K.Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.Cancer Res1995;55:5342-7

[89] Petersen NH,Groth-Pedersen L.Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase.Cancer Cell2013;24:379-93

[90] Perera RM,Nicolay BN.Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism.Nature2015;524:361-5 PMCID:PMC5086585

[91] Aits S.Lysosomal cell death at a glance.J Cell Sci2013;126:1905-12

[92] Cornet-Masana JM,Carbó JM.Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells.EBioMedicine2019;47:221-34 PMCID:PMC6796581

[93] Nielsen IØ,Dicroce-Giacobini J.Cationic amphiphilic drugs induce elevation in lysoglycerophospholipid levels and cell death in leukemia cells.Metabolomics2020;16:91

[94] Duvvuri M,Chatterji D.Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60.J Biol Chem2004;279:32367-72

[95] Zhang S,Vick B.Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.Oncotarget2015;6:43508-28 PMCID:PMC4791247

[96] Dykstra KM,Massey AC.Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis.Blood Adv2021;5:2087-100 PMCID:PMC8095145

[97] Visser N,Huls G,Wiersma VR.Inhibition of autophagy does not re-sensitize acute myeloid leukemia cells resistant to cytarabine.Int J Mol Sci2021;22:2337 PMCID:PMC7956277

[98] Bao EL,Liao X.FinnGen, 23andMe Research TeamInherited myeloproliferative neoplasm risk affects haematopoietic stem cells.Nature2020;586:769-75 PMCID:PMC7606745

[99] Sun L,Lv H.Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth.Cell Chem Biol2021;

[100] Liesveld JL,Walker A.A phase I study of decitabine and rapamycin in relapsed/refractory AML.Leuk Res2013;37:1622-7

[101] Liesveld JL,Azadniv M.A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia.Leuk Res2022;112:106749

[102] Rizzieri DA,Dipersio JF.A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.Clin Cancer Res2008;14:2756-62

[103] Park S,Saint Marcoux F.GOELAMS (Groupe Ouest Est d’Etude des Leucémies aiguës et Autres Maladies du Sang)A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.Leukemia2013;27:1479-86

[104] Bross PF,Chen G.Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.Clin Cancer Res2001;7:1490-6

[105] Petersdorf SH,Slovak M.A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.Blood2013;121:4854-60 PMCID:PMC3682338

[106] Mizutani Y,Maimaitili Y.An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.Int J Hematol2019;110:490-9